Categories Technology

Google bids adieu to AdWords and DoubleClick brands

Alphabet’s (GOOGL) subsidiary Google has decided to rebrand its marketing and advertisement services, and as part of this decision, the company will retire its AdWords and DoubleClick brands. The search engine company is trying to simplify its ad services, making it easier for advertisers to avail of them. Google’s various advertising services have proven to be confusing for its customers in the past and the company is looking to rectify this situation.

Google announced that only the brand names would be taken off and their services would stay the same with no change in the fees. Google has bundled its marketing services into three groups – Google Ads, Google Ad Manager and Google Marketing Platform. AdWords will be renamed as Google Ads and become the primary tool for purchasing advertisements.

Google Ads will serve as a single point of entry for marketers permitting them to gain access to content on Search, Google Play Store, YouTube and other partner services. The AdMob and AdSense brands, which cater to mobile app developers and smaller websites, will remain in service.

Google Ad Manager, aimed at large vendors, will include the DoubleClick Ad Exchange product and the DoubleClick service for publishers. The Google Marketing Platform will comprise of Google Analytics and the advertiser-based DoubleClick service. While the Google Ads platform will be simpler, the Google Marketing Platform will be more sophisticated. All the services will be compatible with other third-party products.

Google’s advertising business has faced criticism over monopoly issues with the company said to be gaining control of more than half of the digital advertisement space alongside Facebook (FB). During the first quarter of 2018, Google’s advertising revenues grew 24% to approximately $27 billion. The simpler and new structure might boost this growth further.

Google ad revenue trend

Most Popular

Context Therapeutics: Another clinical-stage oncology research firm to go public soon

The US primary markets seem to be having a record-breaking start to the year, with over $171 billion raised in the first half of 2021 compared to $168 billion for

Biogen (BIIB) Stock: Does FDA nod for Aduhelm offer a buying opportunity?

The pharmaceutical industry has been witnessing hectic activity for some time, with most drug makers either channelizing their resources for vaccine development or engaging in COVID care programs. Biotechnology giant

IPO News: Monte Rosa Therapeutics will go public this week, here are a few things to know

Biotechnology company Monte Rosa Therapeutics is slated to go public this week. In a pandemic-ridden world, this industry is expanding at a healthy pace. The global biotechnology market is estimated


Add Comment
Viewing Highlight